3.68
-0.06 (-1.60%)
| Previous Close | 3.74 |
| Open | 3.82 |
| Volume | 4,407,981 |
| Avg. Volume (3M) | 5,880,432 |
| Market Cap | 1,280,099,968 |
| Price / Sales | 83.39 |
| Price / Book | 3.41 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -1,913.23% |
| Diluted EPS (TTM) | -2.20 |
| Total Debt/Equity (MRQ) | 2.72% |
| Current Ratio (MRQ) | 9.01 |
| Operating Cash Flow (TTM) | -157.34 M |
| Levered Free Cash Flow (TTM) | -64.76 M |
| Return on Assets (TTM) | -23.33% |
| Return on Equity (TTM) | -119.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Nuvation Bio Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 19.14% |
| % Held by Institutions | 62.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 30 Jun 2025 | 25,954,439 |
| Omega Fund Management, Llc | 30 Jun 2025 | 11,042,728 |
| Laurion Capital Management Lp | 30 Jun 2025 | 10,240,706 |
| Octagon Capital Advisors Lp | 30 Jun 2025 | 7,691,334 |
| Mpm Bioimpact Llc | 30 Jun 2025 | 4,622,590 |
| Tang Capital Management Llc | 30 Jun 2025 | 3,900,000 |
| Abrams Capital Management, L.P. | 30 Jun 2025 | 3,811,513 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (Jefferies, 171.74%) | Buy |
| 10.00 (HC Wainwright & Co., 171.74%) | Buy | |
| Median | 8.50 (130.98%) | |
| Low | 6.00 (Wedbush, 63.04%) | Buy |
| Average | 8.25 (124.19%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 3.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 13 Oct 2025 | 6.00 (63.04%) | Buy | 3.68 |
| 08 Sep 2025 | 6.00 (63.04%) | Buy | 3.49 | |
| Jefferies | 30 Sep 2025 | 10.00 (171.74%) | Buy | 3.70 |
| HC Wainwright & Co. | 19 Sep 2025 | 10.00 (171.74%) | Buy | 3.22 |
| RBC Capital | 08 Aug 2025 | 7.00 (90.22%) | Buy | 2.30 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |